The ESMO-MCBS is a dynamic tool and one of the main tasks of the ESMO-MCBS Working Group is to maintain the scale and to revise when necessary
The ESMO-MCBS Working Group works in the field of development, research, and education regarding the ESMO-MCBS, a reference tool used by many diverse stakeholders in addressing the issue of value in cancer medicines and treatments.
Activities and Responsibilities
- Maintain and update the scale
- Guarantee continual quality assessment that addresses peer and stakeholder feedback and appeals
- Oversee adherence to highest standards of validity and reasonableness in all ESMO-MCBS processes
- Evaluate and score cancer medicines and treatments approved by regulatory bodies such as the European Medicines Agency
- Provide ESMO-MCBS scores for inclusion in the ESMO Clinical Practice Guidelines
- Update ESMO-MCBS scores when new peer-reviewed evidence becomes available
- Promote clear and unbiased communication about the benefits of cancer treatments
- Knowledge sharing of the tool within the global oncology community
Structure
- The ESMO-MCBS Working Group (WG) reports to the Cancer Medicines Committee
- The Chair of the ESMO-MCBS WG is an ex officio position within the Cancer Medicines Committee
See the major achievements of the ESMO-MCBS Working Group
Chair
- Sjoukje Oosting, Netherlands
Working Group Members
- Dirk Arnold, Germany
- Jorge Barriuso, Spain
- Nathan I. Cherny, Israel
- Giuseppe Curigliano, Italy
- Elisabeth G.E. de Vries, Netherlands
- Bishal Gyawali, Canada
- Thomas Hwang, United States of America
- Felipe Roitberg, Brazil
- Manju Sengar, India
- Elizabeth Smyth, United Kingdom
- Dario Trapani, Italy
Extended Working Group Members
- Teresa Amaral, Germany
- Eva Blondeaux, Italy
- Martin Dreyling, Germany
- Roberto Ferrara, Italy
- Barbara Kiesewetter, Austria
- Emre Kocakavuk, Germany
- Alexios Matikas, Sweden
- Aju Mathew, India
- David McMahon, Ireland
- Tomer Meirson, Israel
- Madeleine Pe, Belgium
- Martine Piccart, Belgium
- Miroslawa Puskulluoglu, Poland
- Rozemarijn van Rijn, Netherlands
- José Luis Sandoval, Switzerland
- Eva Segelov, Switzerland
- Johan Vansteenkiste, Belgium
- Bernhard Woermann, Germany
- Hongcheng Zhu, China
Biostatistical support provided by Frontier Science Foundation - Hellas
Last update: April 2025